JP2021039112A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021039112A5 JP2021039112A5 JP2020185705A JP2020185705A JP2021039112A5 JP 2021039112 A5 JP2021039112 A5 JP 2021039112A5 JP 2020185705 A JP2020185705 A JP 2020185705A JP 2020185705 A JP2020185705 A JP 2020185705A JP 2021039112 A5 JP2021039112 A5 JP 2021039112A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- aki
- hours
- body fluid
- fluid sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010038436 Renal failure acute Diseases 0.000 claims 14
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 13
- 210000001124 Body Fluids Anatomy 0.000 claims 11
- 239000010839 body fluid Substances 0.000 claims 11
- 230000002688 persistence Effects 0.000 claims 9
- 229940109239 Creatinine Drugs 0.000 claims 4
- 210000002966 Serum Anatomy 0.000 claims 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims 4
- 230000035957 Urine Volume Effects 0.000 claims 3
- 238000004166 bioassay Methods 0.000 claims 3
- 206010038435 Renal failure Diseases 0.000 claims 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 2
- 201000006370 kidney failure Diseases 0.000 claims 2
- 201000011461 pre-eclampsia Diseases 0.000 claims 2
- 230000000268 renotropic Effects 0.000 claims 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17 Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 102000019034 Chemokines Human genes 0.000 claims 1
- 108010012236 Chemokines Proteins 0.000 claims 1
- 210000004351 Coronary Vessels Anatomy 0.000 claims 1
- 229940119017 Cyclosporine Drugs 0.000 claims 1
- 108010036949 Cyclosporine Proteins 0.000 claims 1
- 206010012601 Diabetes mellitus Diseases 0.000 claims 1
- 102000001554 Hemoglobins Human genes 0.000 claims 1
- 108010054147 Hemoglobins Proteins 0.000 claims 1
- 206010019641 Hepatic cirrhosis Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N Ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims 1
- 229960001101 Ifosfamide Drugs 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 102000036913 Myoglobin Human genes 0.000 claims 1
- 108010062374 Myoglobin Proteins 0.000 claims 1
- 229960001052 Streptozocin Drugs 0.000 claims 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N Streptozotocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 claims 1
- 229960001967 Tacrolimus Drugs 0.000 claims 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims 1
- 201000003126 anuria Diseases 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 238000007675 cardiac surgery Methods 0.000 claims 1
- 229960001265 ciclosporin Drugs 0.000 claims 1
- 201000006233 congestive heart failure Diseases 0.000 claims 1
- 239000002872 contrast media Substances 0.000 claims 1
- 201000008739 coronary artery disease Diseases 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 230000024924 glomerular filtration Effects 0.000 claims 1
- 229910001385 heavy metal Inorganic materials 0.000 claims 1
- 201000004044 liver cirrhosis Diseases 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 201000001474 proteinuria Diseases 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
Claims (20)
- 対象における急性腎障害（ＡＫＩ）の将来の持続のリスクを評価するための方法であって、
アッセイ結果を得るために、前記対象から得られた体液試料においてＣ−Ｃモチーフケモカイン１４を検出するように構成されたアッセイを実施するステップと；
前記アッセイ結果を前記対象のＡＫＩの将来の持続のリスクに相関させるステップと、
を含み、
前記相関させるステップが、ＡＫＩの将来の持続の既知の素因を有する個体の亜集団に前記対象を割り付けることを含む、
方法。 - 前記対象は、前記体液試料が得られた時点でＡＫＩを有する、請求項１に係る方法。
- 腎前性、腎性または腎後性のＡＫＩに関する１つまたは複数の既知の危険因子が前記対象において以前から存在することに基づいて、または大血管手術、冠動脈バイパス術もしくは他の心臓手術を受けている、もしくは受けたことがあることに基づいて、またはＮＳＡＩＤ、シクロスポリン、タクロリムス、アミノグリコシド、ホスカルネット、エチレングリコール、ヘモグロビン、ミオグロビン、イホスファミド、重金属、メトトレキサート、放射線不透過性造影剤もしくはストレプトゾトシンへの暴露に基づいて、ＡＫＩの将来の持続のリスクの評価のために前記対象が選択され、
前記１つまたは複数の既知の危険因子は、うっ血性心不全、子癇前症、子癇、糖尿病、高血圧、冠動脈疾患、タンパク尿、腎不全、正常範囲未満の糸球体濾過値、肝硬変、正常範囲を超える血清クレアチニン、敗血症、腎機能損傷、腎機能低下もしくはＡＲＦのうちの１つもしくは複数の既存の診断から選択される、
請求項１または２に記載の方法。 - ＡＫＩの将来の持続が、前記体液試料が得られた時点から７２時間以内に起こる、請求項１〜３のいずれか１項に記載の方法。
- ＡＫＩの将来の持続が、前記体液試料が得られた時点から４８時間以内に起こる、請求項１〜３のいずれか１項に記載の方法。
- ＡＫＩの将来の持続が、前記体液試料が得られた時点から２４時間以内に起こる、請求項１〜３のいずれか１項に記載の方法。
- ＡＫＩが、２１日間、１４日間、７日間、５日間、９６時間、７２時間、４８時間、３６時間、２４時間または１２時間にわたって持続することになる、請求項１〜６のいずれか１項に記載の方法。
- 前記対象が、ＲＩＦＬＥステージＲである、請求項１〜７のいずれか１項に記載の方法。
- 前記対象が、ＲＩＦＬＥステージＩである、請求項１〜７のいずれか１項に記載の方法。
- 前記対象が、ＲＩＦＬＥステージＦである、請求項１〜７のいずれか１項に記載の方法。
- 前記対象に、最小ＲＩＦＬＥステージがＲＩＦＬＥ ＩであるＡＫＩの持続の将来的なリスクがある、請求項１〜１０のいずれか１項に記載の方法。
- 前記対象に、最小ＲＩＦＬＥステージがＲＩＦＬＥ ＦであるＡＫＩの持続の将来的なリスクがある、請求項１〜１０のいずれか１項に記載の方法。
- 前記対象は、前記体液試料が得られた時点より前に測定されたベースライン値の１．５倍以上の血清クレアチニン増加に見舞われる、請求項１〜１２のいずれか１項に記載の方法。
- 前記対象は、前記体液試料が得られた時点より前の６時間の間の尿量が０．５ｍｌ／ｋｇ体重／時間よりも少ない、請求項１〜１３のいずれか１項に記載の方法。
- 前記対象は、前記体液試料が得られた時点より前に測定されたベースライン値の２倍以上の血清クレアチニン増加に見舞われる、請求項１〜７または９〜１２のいずれか１項に記載の方法。
- 前記対象は、前記体液試料が得られた時点より前の１２時間の間の尿量が０．５ｍｌ／ｋｇ／時間よりも少ない、請求項１〜７、９〜１２または１５のいずれか１項に記載の方法。
- 前記対象は、前記体液試料が得られた時点より前に測定されたベースライン値の３倍以上の血清クレアチニン増加に見舞われる、請求項１〜７または１０〜１２のいずれか１項に記載の方法。
- 前記対象は、前記体液試料が得られた時点より前に測定されたベースライン値に比べて少なくとも４４μｍｏｌ／Ｌの血清クレアチニン増加を伴う３５５μｍｏｌ／Ｌ以上の血清クレアチニンレベルを有する、請求項１〜７、１０〜１２または１７のいずれか１項に記載の方法。
- 前記対象は、前記体液試料が得られた時点より前の２４時間の間の尿量が０．３ｍｌ／ｋｇ／時間よりも少ない、請求項１〜７、１０〜１２または１７〜１８のいずれか１項に記載の方法。
- 前記対象は、前記体液試料が得られた時点より前の１２時間の間、無尿である、１〜７、１０〜１２または１７〜１９のいずれか１項に記載の方法。
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021211779A JP7217796B2 (ja) | 2014-10-20 | 2021-12-27 | 腎障害および腎不全の診断および予後のための方法および組成物 |
| JP2023008480A JP2023052587A (ja) | 2014-10-20 | 2023-01-24 | 腎障害および腎不全の診断および予後のための方法および組成物 |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462066310P | 2014-10-20 | 2014-10-20 | |
| US201462066313P | 2014-10-20 | 2014-10-20 | |
| US201462066316P | 2014-10-20 | 2014-10-20 | |
| US62/066,316 | 2014-10-20 | ||
| US62/066,310 | 2014-10-20 | ||
| US62/066,313 | 2014-10-20 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017521231A Division JP6792553B2 (ja) | 2014-10-20 | 2015-10-20 | 腎障害および腎不全の診断および予後のための方法および組成物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021211779A Division JP7217796B2 (ja) | 2014-10-20 | 2021-12-27 | 腎障害および腎不全の診断および予後のための方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021039112A JP2021039112A (ja) | 2021-03-11 |
| JP2021039112A5 true JP2021039112A5 (ja) | 2021-09-24 |
| JP7002623B2 JP7002623B2 (ja) | 2022-02-10 |
Family
ID=55761743
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017521231A Active JP6792553B2 (ja) | 2014-10-20 | 2015-10-20 | 腎障害および腎不全の診断および予後のための方法および組成物 |
| JP2020185705A Active JP7002623B2 (ja) | 2014-10-20 | 2020-11-06 | 腎障害および腎不全の診断および予後のための方法および組成物 |
| JP2021211779A Active JP7217796B2 (ja) | 2014-10-20 | 2021-12-27 | 腎障害および腎不全の診断および予後のための方法および組成物 |
| JP2023008480A Pending JP2023052587A (ja) | 2014-10-20 | 2023-01-24 | 腎障害および腎不全の診断および予後のための方法および組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017521231A Active JP6792553B2 (ja) | 2014-10-20 | 2015-10-20 | 腎障害および腎不全の診断および予後のための方法および組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021211779A Active JP7217796B2 (ja) | 2014-10-20 | 2021-12-27 | 腎障害および腎不全の診断および予後のための方法および組成物 |
| JP2023008480A Pending JP2023052587A (ja) | 2014-10-20 | 2023-01-24 | 腎障害および腎不全の診断および予後のための方法および組成物 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11333671B2 (ja) |
| EP (2) | EP3968022A1 (ja) |
| JP (4) | JP6792553B2 (ja) |
| KR (1) | KR102431003B1 (ja) |
| CN (2) | CN107003301B (ja) |
| AU (2) | AU2015336069B2 (ja) |
| BR (1) | BR112017008218A2 (ja) |
| CA (1) | CA2965153C (ja) |
| EA (1) | EA201790696A1 (ja) |
| ES (1) | ES2907551T3 (ja) |
| MX (1) | MX2017005126A (ja) |
| PT (1) | PT3210018T (ja) |
| WO (1) | WO2016064877A2 (ja) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107003301B (zh) | 2014-10-20 | 2019-11-01 | 阿斯图特医药公司 | 用于诊断和预后肾损伤和肾衰竭的方法和组合物 |
| EP3568695A4 (en) * | 2017-01-12 | 2020-12-16 | Astute Medical, Inc. | METHODS AND COMPOSITIONS FOR THE EVALUATION AND TREATMENT OF KIDNEY INJURY AND RENAL FAILURE BASED ON A MEASUREMENT OF LIGAND CHEMIOKINE ON C-C 14 |
| EP3577458A4 (en) | 2017-02-06 | 2021-04-07 | Astute Medical, Inc. | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PREDICTION OF RENAL LESION AND RENAL INSUFFICIENCY |
| CN112041341B (zh) | 2017-12-28 | 2024-05-24 | 机敏医药股份有限公司 | Ccl14的抗体和检测 |
| EP3761876A4 (en) * | 2018-04-02 | 2021-12-22 | Potrero Medical, Inc. | SYSTEMS, DEVICES AND METHODS FOR BODY FLUID DRAINAGE AND ANALYSIS AND HEALTH ASSESSMENT |
| US20220236285A1 (en) * | 2019-05-24 | 2022-07-28 | Astute Medical, Inc. | Methods for evaluation and treatment of renal injury based on c-c motif chemokine ligand 14 measurement |
| GB2596142B (en) * | 2020-06-19 | 2023-11-29 | Secr Defence | Methods and associated uses, kits and systems for assessing sepsis |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5939272A (en) | 1989-01-10 | 1999-08-17 | Biosite Diagnostics Incorporated | Non-competitive threshold ligand-receptor assays |
| US5028535A (en) | 1989-01-10 | 1991-07-02 | Biosite Diagnostics, Inc. | Threshold ligand-receptor assay |
| US5922615A (en) | 1990-03-12 | 1999-07-13 | Biosite Diagnostics Incorporated | Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network |
| AU658374B2 (en) | 1990-09-14 | 1995-04-13 | Biosite Diagnostics Incorporated | Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays |
| US5955377A (en) | 1991-02-11 | 1999-09-21 | Biostar, Inc. | Methods and kits for the amplification of thin film based assays |
| WO1992018868A1 (en) | 1991-04-10 | 1992-10-29 | Biosite Diagnostics Incorporated | Crosstalk inhibitors and their uses |
| DE69231382T2 (de) | 1991-04-12 | 2001-01-25 | Biosite Diagnostics Inc | Neue konjugate und testverfahren für die gleichzeitige bestimmung von multiplen liganden |
| US6143576A (en) | 1992-05-21 | 2000-11-07 | Biosite Diagnostics, Inc. | Non-porous diagnostic devices for the controlled movement of reagents |
| US5885527A (en) | 1992-05-21 | 1999-03-23 | Biosite Diagnostics, Inc. | Diagnostic devices and apparatus for the controlled movement of reagents without membrances |
| US5494829A (en) | 1992-07-31 | 1996-02-27 | Biostar, Inc. | Devices and methods for detection of an analyte based upon light interference |
| US5824799A (en) | 1993-09-24 | 1998-10-20 | Biosite Diagnostics Incorporated | Hybrid phthalocyanine derivatives and their uses |
| US6811773B1 (en) * | 1993-12-22 | 2004-11-02 | Human Genome Sciences, Inc. | Human monocyte colony inhibitory factor (M-CIF) polypeptides |
| US6113855A (en) | 1996-11-15 | 2000-09-05 | Biosite Diagnostics, Inc. | Devices comprising multiple capillarity inducing surfaces |
| US5947124A (en) | 1997-03-11 | 1999-09-07 | Biosite Diagnostics Incorporated | Diagnostic for determining the time of a heart attack |
| US6057098A (en) | 1997-04-04 | 2000-05-02 | Biosite Diagnostics, Inc. | Polyvalent display libraries |
| US20030157573A1 (en) | 2002-02-12 | 2003-08-21 | Orna Mor | Use of Axl receptor for diagnosis and treatment of renal disease |
| US20120064089A1 (en) * | 2002-11-15 | 2012-03-15 | Morehouse School Of Medicine | Anti-cxcl16 and anti-cxcr6 antibodies for the prevention and treatment of cancer and cancer cell migration |
| EP1915614A4 (en) | 2005-07-21 | 2009-03-25 | Univ Johns Hopkins | ACUTE RENAL FAILURE |
| EP1996013A4 (en) | 2005-09-21 | 2010-03-10 | Dask Technologies Llc | METHODS AND COMPOSITIONS FOR FUNCTIONALITY OF ORGANS AND TISSUES |
| WO2009038742A2 (en) | 2007-09-20 | 2009-03-26 | Caritas St. Elizabeth's Medical Center Of Boston, Inc. | Method for estimating risk of acute kidney injury |
| WO2009114110A1 (en) | 2008-03-08 | 2009-09-17 | Immungene, Inc. | Engineered fusion molecules immunotherapy in cancer and inflammatory diseases |
| NZ619918A (en) | 2008-10-21 | 2015-04-24 | Astute Medical Inc | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| EP2462437A4 (en) * | 2009-08-07 | 2013-01-30 | Rules Based Medicine Inc | METHOD AND DEVICES FOR DETECTING DIABETIC NEPHROPATHY AND ASSOCIATED DISEASES THEREOF |
| CA2774223A1 (en) * | 2009-09-21 | 2011-03-24 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| CN102725635B (zh) * | 2009-11-07 | 2015-05-20 | 阿斯图特医药公司 | 用于肾损伤和肾衰竭的诊断及预后的方法和组合物 |
| NZ600160A (en) * | 2009-11-07 | 2014-05-30 | Astute Medical Inc | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| US20120156701A1 (en) * | 2009-12-20 | 2012-06-21 | Joseph Anderberg | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| ES2818138T3 (es) | 2009-12-20 | 2021-04-09 | Astute Medical Inc | Métodos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal |
| KR101940014B1 (ko) * | 2010-02-05 | 2019-01-21 | 아스튜트 메디컬 인코포레이티드 | 신손상 및 신부전을 진단 및 예측하는 방법 및 조성물 |
| EA201291314A1 (ru) * | 2010-06-23 | 2013-11-29 | Астьют Медикал, Инк. | Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности |
| NZ703055A (en) * | 2010-06-23 | 2016-07-29 | Astute Medical Inc | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| AU2011269775B2 (en) | 2010-06-23 | 2015-01-15 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| UY33492A (es) * | 2010-07-09 | 2012-01-31 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| EP2694974B1 (en) | 2011-04-04 | 2015-10-21 | Universiteit Gent | Biomarkers for acute kidney injury |
| PT2748605T (pt) | 2011-08-26 | 2019-05-03 | Astute Medical Inc | Processos e composições para o diagnóstico e o prognóstico de lesões renais e de insuficiência renal |
| US10935548B2 (en) | 2011-12-08 | 2021-03-02 | Astute Medical, Inc. | Methods for diagnosis and prognosis of renal injury and renal failure using insulin-like growth factor-binding protein 7 and metalloproteinase inhibitor 2 |
| WO2013096740A1 (en) * | 2011-12-21 | 2013-06-27 | Alere San Diego Inc. | Methods and compositions for assigning likelihood of chronic kidney disease progression |
| US20160003850A1 (en) | 2013-02-26 | 2016-01-07 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| CN107003301B (zh) | 2014-10-20 | 2019-11-01 | 阿斯图特医药公司 | 用于诊断和预后肾损伤和肾衰竭的方法和组合物 |
-
2015
- 2015-10-20 CN CN201580068922.9A patent/CN107003301B/zh active Active
- 2015-10-20 EP EP21186630.6A patent/EP3968022A1/en active Pending
- 2015-10-20 JP JP2017521231A patent/JP6792553B2/ja active Active
- 2015-10-20 PT PT15853584T patent/PT3210018T/pt unknown
- 2015-10-20 WO PCT/US2015/056462 patent/WO2016064877A2/en active Application Filing
- 2015-10-20 AU AU2015336069A patent/AU2015336069B2/en active Active
- 2015-10-20 KR KR1020177013539A patent/KR102431003B1/ko active IP Right Grant
- 2015-10-20 CA CA2965153A patent/CA2965153C/en active Active
- 2015-10-20 ES ES15853584T patent/ES2907551T3/es active Active
- 2015-10-20 EP EP15853584.9A patent/EP3210018B1/en active Active
- 2015-10-20 US US15/520,817 patent/US11333671B2/en active Active
- 2015-10-20 EA EA201790696A patent/EA201790696A1/ru unknown
- 2015-10-20 MX MX2017005126A patent/MX2017005126A/es unknown
- 2015-10-20 CN CN201910986041.5A patent/CN110702921B/zh active Active
- 2015-10-20 BR BR112017008218A patent/BR112017008218A2/pt not_active Application Discontinuation
-
2020
- 2020-11-06 JP JP2020185705A patent/JP7002623B2/ja active Active
-
2021
- 2021-12-27 JP JP2021211779A patent/JP7217796B2/ja active Active
-
2022
- 2022-02-21 AU AU2022201130A patent/AU2022201130B2/en active Active
- 2022-03-31 US US17/710,832 patent/US20220236286A1/en active Pending
-
2023
- 2023-01-24 JP JP2023008480A patent/JP2023052587A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021039112A5 (ja) | ||
| JP2013519095A5 (ja) | ||
| JP2012517594A5 (ja) | ||
| JP2013503344A5 (ja) | ||
| Al-Khoury et al. | Anaemia in diabetic patients with chronic kidney disease—prevalence and predictors | |
| JP2013510321A5 (ja) | ||
| HRP20160733T1 (hr) | Postupci i pripravci za postavljanje dijagnoze i prognoze ozljede bubrega i bubrežne insuficijencije | |
| JP2017533427A5 (ja) | ||
| JP2013531240A5 (ja) | ||
| JP2012517592A5 (ja) | ||
| JP2013539861A5 (ja) | ||
| Anderson et al. | Clinical and laboratory diagnosis of acute renal failure | |
| JP2015129764A5 (ja) | ||
| JP2013513086A5 (ja) | ||
| Ghadirpour et al. | Renal vascular Doppler ultrasonographic indices and carotid artery intima-media thickness in diabetic nephropathy | |
| Yen et al. | Cardiothoracic ratio, inflammation, malnutrition, and mortality in diabetes patients on maintenance hemodialysis | |
| JP2017534874A5 (ja) | ||
| Olawale et al. | Assessment of renal function status in steady-state sickle cell anaemic children using urine human neutrophil gelatinase-associated lipocalin and albumin: creatinine ratio | |
| Jabbarov | Disorders Function of the Heart and Kidney in Diabetes Mellitus | |
| JP2015508181A5 (ja) | ||
| Mihajlov et al. | Albuminuria and glomerular filtration in patients with essential hypertension | |
| Mahajan et al. | Assessing suitability for renal donation: can equations predicting glomerular filtration rate substitute for a reference method in the Indian population? | |
| WO2011105474A1 (ja) | 急性腎障害の検査方法 | |
| Hamm et al. | Kidney disease as a risk factor for development of cardiovascular disease | |
| CN108291903A (zh) | 糖尿病性肾病的判定标志物 |